Evidence map›Paper›PMID 37662356›Full record

ArticlebioRxiv : the preprint server for biology2023

Comprehensive mapping of cell fates in microsatellite unstable cancer cells support dual targe6ng of WRN and ATR.

Dali Zong, Natasha C Koussa, James A Cornwell, Ajith V Pankajam, Michael J Kruhlak, Nancy Wong, Raj Chari, Steven D Cappell, André Nussenzweig

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dali ZongLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Natasha C KoussaLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
James A CornwellLaboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ajith V PankajamLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Michael J KruhlakLaboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nancy WongLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Raj ChariGenome Modification Core, Frederick National Lab for Cancer Research, Frederick, MD, USA.
Steven D CappellLaboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
André NussenzweigLaboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
National Institutes of Health · USFrederick National Laboratory for Cancer Research · US

Funding

Control of cell cycle commitment by APCC-Cdh1ZIABC011830 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CAPPELL, STEVEN · 2018 to 2025
$4.7M
Intramural NIH HHS ZIA BC011830NCI NIH HHS HHSN261201000031CNCI NIH HHS HHSN261201500001CNCI NIH HHS HHSN261201500001GNCI NIH HHS HHSN261201500001WNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003I
6 · The paper itself

Abstract

Addiction to the WRN helicase is a unique vulnerability of human cancers with high levels of microsatellite instability (MSI-H). However, while prolonged loss of WRN ultimately leads to cell death, little is known about how MSI-H cancers initially respond to acute loss of WRN, knowledge that would be helpful for informing clinical development of WRN-targeting therapy, predicting possible resistance mechanisms, and identifying useful biomarkers of successful WRN inhibition. Here, we report the construction of an inducible ligand-mediated degradation system wherein the stability of endogenous WRN protein can be rapidly and specifically tuned, enabling us to track the complete sequence of cellular events elicited by acute loss of WRN function. We find that WRN degradation leads to immediate accrual of DNA damage in a replication-dependent manner that curiously did not robustly engage checkpoint mechanisms to halt DNA synthesis. As a result, WRN-degraded MSI-H cancer cells accumulate DNA damage across multiple replicative cycles and undergo successive rounds of increasingly aberrant mitoses, ultimately triggering cell death. Of potential therapeutic importance, we find no evidence of any generalized mechanism by which MSI-H cancers could adapt to near-complete loss of WRN. However, under conditions of partial WRN degradation, addition of low dose ATR inhibitor significantly increased their combined efficacy to levels approaching full inactivation of WRN. Overall, our results provided the first comprehensive view of molecular events linking upstream inhibition of WRN to subsequent cell death and suggested a potential therapeutical rationale for dual targeting of WRN and ATR.

Identifiers

PMID37662356
PMCPMC10473727
OpenAlexW4385400362

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.